Barinthus Biotherapeutics plc
BRNS
$0.8201
-$0.0029-0.35%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -20.54M | -8.11M | -16.93M | -15.49M | -17.29M |
| Total Depreciation and Amortization | 628.00K | 675.00K | 667.00K | 630.00K | 635.00K |
| Total Amortization of Deferred Charges | 800.00K | 800.00K | 800.00K | 800.00K | 800.00K |
| Total Other Non-Cash Items | 17.05M | 3.73M | 2.00M | 952.00K | 7.14M |
| Change in Net Operating Assets | 15.15M | -15.29M | 1.46M | 1.29M | -10.88M |
| Cash from Operations | 13.09M | -18.20M | -12.01M | -11.82M | -19.60M |
| Capital Expenditure | -278.00K | -114.00K | -192.00K | -308.00K | 153.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -278.00K | -114.00K | -192.00K | -308.00K | 153.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 837.00K | 465.00K | 358.00K | 503.00K | 109.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 0.00 |
| Cash from Financing | 837.00K | 465.00K | 358.00K | 503.00K | 109.00K |
| Foreign Exchange rate Adjustments | -7.35M | 6.18M | -357.00K | -492.00K | 1.12M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 6.30M | -11.67M | -12.20M | -12.12M | -18.22M |